Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today presented results from a Phase II study that compared the combinations of...
First Arginine Vasopressin (AVP) Antagonist Approved for the Management of Potentially Life-Threatening Sodium and Water Imbalance PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. today...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 17, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship...
Acquisition of psoriasis product deepens Astellas’ Commitment to Dermatology franchise Deerfield, IL and Cambridge, MA, April 3, 2006 – Astellas Pharma US, Inc. and Biogen Idec Inc. (NASDAQ:...
Heart indication for Prograf reinforces a 20-year commitment to research and development in transplantation DEERFIELD, IL, APRIL 1, 2006 – The Food and Drug Administration (FDA) has granted...
Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced...
MELVILLE, N.Y., Feb 01, 2006 -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva® (erlotinib). Net international sales...
Recently, new information was added to the US labeling for the class of topical calcineurin inhibitors, or TCIs, which includes Protopic® (tacrolimus) Ointment and pimecrolimus cream. The new...
MELVILLE, N.Y., Jan 11, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter and year-end net U.S. sales for its flagship product, Tarceva® (erlotinib)....
First arginine vasopressin (AVP) antagonist approved for the management of potentially lifethreatening sodium/water imbalance DEERFIELD, Illinois, December 30 — Astellas Pharma US, Inc. today...
Read more about FDA Approves Astellas' Vaprisol® for the Treatment of Euvolemic Hyponatremia
Follow U.S. news
